Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Vebreltinib Combined With Platinum-Doublet Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Negative Driver Genes and MET Overexpression

NCT07549061 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT07549061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07549061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Vebreltinib Combined With Platinum-Doublet Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Negative Driver Genes and MET Overexpression
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 30, 2026
Completion date
December 30, 2028
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms